Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

Tan, DSW; Felip, E; de Castro, G; Solomon, BJ; Greystoke, A; Cho, BC; Cobo, M; Kim, TM; Ganguly, S; Carcereny, E; Paz-Ares, L; Bennouna, J; Garassino, MC; Schenker, M; Kim, SW; Brase, JC; Bury-Maynard, D; Passos, VQ; Deudon, S; Dharan, B; Song, Y; Caparica, R; Johnson, BE

Author(s): Tan, DSW; Felip, E; de Castro, G; Solomon, BJ; Greystoke, A; Cho, BC; Cobo, M; Kim, TM; Ganguly, S; Carcereny, E; Paz-Ares, L; Bennouna, J; Garassino, MC; Schenker, M; Kim, SW; Brase, JC; Bury-Maynard, D; Passos, VQ; Deudon, S; Dharan, B; Song, Y; Caparica, R; Johnson, BE;
Details: Publication Year 2024-01-10,Volume 42,Issue #2,Page 192-204
Journal Title: Journal of Clinical Oncology
Publication Type: Research article
Abstract: PURPOSE: The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non-small-cell lung cancer (NSCLC), but prognosis remains poor, with new treatment options needed. Canakinumab, a human, monoclonal anti-interleukin (IL)-1β antibody, has potential to enhance the activity of PD-L1 inhibitors and chemotherapy (CT) by inhibiting protumor inflammation. METHODS: CANOPY-1 was a phase III, randomized, double-blind study comparing canakinumab (200 mg subcutaneously once every 3 weeks) versus placebo, both combined with pembrolizumab (200 mg intravenously once every 3 weeks) and platinum-based doublet CT, as first-line treatment for advanced/metastatic NSCLC without EGFR or ALK mutations. The primary end points were progression-free survival (PFS) and overall survival (OS). The secondary endpoints included overall response rate, safety, and patient-reported outcomes. RESULTS: Overall, 643 patients were randomly assigned to canakinumab (n = 320) or placebo (n = 323). With a median study follow-up of 6.5 months, the median PFS was 6.8 months with canakinumab versus 6.8 months with placebo (hazard ratio [HR], 0.85; 95% CI, 0.67 to 1.09; P = .102). With a median study follow-up of 21.2 months, the median OS was 20.8 months with canakinumab versus 20.2 months with placebo (HR, 0.87; 95% CI, 0.70 to 1.10; P = .123). No unexpected safety signals were observed for canakinumab combination. Infection rates were comparable between treatment and control arms. A higher frequency of neutropenia and ALT increase (grade ≤2) were reported in the treatment arm. Higher baseline C-reactive protein and IL-6 levels were associated with shorter PFS and OS. Patients treated with canakinumab had clinically meaningful delays in deterioration of lung cancer symptoms, including chest pain and coughing per LC13 and dyspnea per LC13 and C30. CONCLUSION: The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC.
Publisher: American Society of Clinical Oncology
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung/pathology; *Lung Neoplasms/pathology; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1200/jco.23.00980
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-02-22 12:10:31

Last Modified: 2024-02-22 12:22:36